Table 8. Effectiveness of montelukast compared to placebo in the low ECP group (ECP <15 µg/L).

	Changes after taking Montelukast (Mean±SD)	Changes after taking Placebo drug (Mean±SD)	P value
SCORAD index	-3.7±11.9	-4.1±11.4	0.93
Urine LTE4 (pg/mL)	-111.2± 562.5	41.0±712.2	0.39
Urine EDN (ng/mL)	348.1±1,026.2	-169.0±838.9	0.03

ECP, eosinophil cationic protein; SCORAD, SCORing Atopic Dermatitis; LTE₄, leukotriene E₄; EDN, eosinophil-derived neurotoxin.